TY - JOUR
T1 - Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma
T2 - A nationwide case series of 35 patients in The Netherlands
AU - Boon, Eline
AU - van Boxtel, Wim
AU - Buter, Jan
AU - de Jong, Robert J. Baatenburg
AU - van Es, Robert J. J.
AU - Bel, Miranda
AU - Fiets, Edward
AU - Oosting, Sjoukje F.
AU - Slingerland, Marije
AU - Hoeben, Ann
AU - Tesselaar, Margot E. T.
AU - Jonker, Marianne A.
AU - Flucke, Uta E.
AU - van der Graaf, Winette T. A.
AU - van Herpen, Carla M. L.
AU - Nationwide Network; Registry Histopathology Cytopathol
PY - 2018/3/1
Y1 - 2018/3/1
N2 - BackgroundSalivary duct carcinoma, an aggressive subtype of salivary gland cancer, is mostly androgen receptor-positive. Only limited data are available on androgen deprivation therapy (ADT). MethodsPatients with advanced androgen receptor-positive salivary duct carcinoma treated with first-line ADT were retrospectively evaluated for clinical benefit (ie, partial response [PR] and stable disease, progression-free survival [PFS] and overall survival [OS]). The OS was compared with patients with advanced salivary duct carcinoma who received best supportive care. ResultsThirty-four of 35 patients who were ADT-treated were evaluable: 6 patients had a PR (18%) and 11 had stable disease (32%) leading to a clinical benefit ratio of 50%. The median PFS for the ADT-treated patients was 4 months and the median duration of clinical benefit was 11 months. The median OS was 17 months versus 5 months in 43 patients receiving best supportive care (P=.02). ConclusionWe recommend ADT in advanced androgen receptor-positive salivary duct carcinoma given its response and clinical benefit. (c) 2017 Wiley Periodicals, Inc. Head Neck, 2017
AB - BackgroundSalivary duct carcinoma, an aggressive subtype of salivary gland cancer, is mostly androgen receptor-positive. Only limited data are available on androgen deprivation therapy (ADT). MethodsPatients with advanced androgen receptor-positive salivary duct carcinoma treated with first-line ADT were retrospectively evaluated for clinical benefit (ie, partial response [PR] and stable disease, progression-free survival [PFS] and overall survival [OS]). The OS was compared with patients with advanced salivary duct carcinoma who received best supportive care. ResultsThirty-four of 35 patients who were ADT-treated were evaluable: 6 patients had a PR (18%) and 11 had stable disease (32%) leading to a clinical benefit ratio of 50%. The median PFS for the ADT-treated patients was 4 months and the median duration of clinical benefit was 11 months. The median OS was 17 months versus 5 months in 43 patients receiving best supportive care (P=.02). ConclusionWe recommend ADT in advanced androgen receptor-positive salivary duct carcinoma given its response and clinical benefit. (c) 2017 Wiley Periodicals, Inc. Head Neck, 2017
KW - androgen deprivation therapy
KW - androgen receptors
KW - antineoplastic agents
KW - hormonal
KW - salivary duct carcinoma
KW - salivary gland neoplasms
KW - TRASTUZUMAB
KW - COMBINATION
KW - CANCERS
KW - HER2
U2 - 10.1002/hed.25035
DO - 10.1002/hed.25035
M3 - Article
C2 - 29272069
SN - 1043-3074
VL - 40
SP - 605
EP - 613
JO - Head and Neck-Journal for the Sciences and Specialties of the Head and Neck
JF - Head and Neck-Journal for the Sciences and Specialties of the Head and Neck
IS - 3
ER -